CONMED Corp (NYSE: CNMD) has reported E.P.S. of $1.59 for its third fiscal quarter (ending September 30) versus $0.52 for the same period a year ago — an increase of 206%. E.P.S. were $4.28 for the latest four quarters through September 30 versus $1.89 for the same period a year ago — an increase of 126%.
Recent Price Action
On 10/30/24, CONMED Corp (NYSE: CNMD) stock rose modestly by 0.9%, closing at $65.26. Moreover, above average trading volume at 138% of normal accompanied the advance. The stock has been weak relative to the market over the last nine months but has risen 3.5% during the last week.
Current PriceTarget Research Rating
CNMD’s future returns on capital are forecasted to exceed the cost of capital. Accordingly, the company is expected to continue to be a major Value Builder.
CONMED has a current Value Trend Rating of D (Negative). This rating combines inconsistent signals from two proprietary PTR measures of a stock’s attractiveness. CONMED has a neutral Appreciation Score of 46 but a poor Power Rating of 25, resulting in the Negative Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment